Contact us at (800) USC-CARE (800-872-2273)

Listing

Umbrella_KeckMedicine
umbrella-logo
Keck Medicine of USC is the University of Southern California’s medical enterprise, one of only two university-owned academic medical centers in the Los Angeles area.
Listing2019-07-17T16:00:54+00:00

NCTID
NCT03524612

A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids

Type:

NCTID
NCT03693170

Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer

Type:

Read More

Description

The presence of a BRAFV600E mutation is considered a marker of poor prognosis in subjects
with mCRC. The preclinical results and preliminary clinical data together justify the
evaluation of this triple combination in the first-line setting of this population. The
primary objective of the study is to evaluate the antitumor activity of the combination of
encorafenib, binimetinib and cetuximab by assessing the overall response rate in adult
subjects with previously untreated BRAFV600E-mutant metastatic colorectal cancer. It will
also assess the effect of the triple combination on the duration of response, time to
response, progression-free survival and overall survival and assess the effect on quality of
life. It will also characterize the safety and tolerability of the triple combination as well
as describe the pharmacokinetics (PK) of encorafenib, binimetinib, and cetuximab.

NCTID

Join today! New study at USC tests effectiveness of newly approved drug to help people with eczema, called Atopic Dermatitis

Type:

Read More

Description

Atopic Dermatitis is a form of eczema that causes dry, scaly, itchy skin. More than 3 million cases are reported in the U.S. each year. People with this skin condition often have problems with bacterial skin infections caused by a specific bacteria known as, Staph aureus, or just Staph. Patients with chronic eczema often use long-term topical or oral treatments to help control their symptoms. But using these medications over long periods of time can have side effects on the body. The purpose of this study is to test the effectiveness of the drug dupilumab (dupixent), which was recently approved by the Food and Drug Administration (FDA) to offer relief to patients who cannot control their eczema with commonly used topical medications.We want to find out how dupilumab affects the amount of bacteria on the skin and the immune system of the patients, and whether it might cause less side effects. Join us today if you are between 18-65 years old with chronic eczema (Atopic Dermatitis).

NCTID
NCT03726489

A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis

Type:

Read More

Description

The primary objective of this study is to compare the effectiveness, safety (tolerability),
and duration of treatment response at 12 weeks of home versus office-based narrowband
ultraviolet B phototherapy for the treatment of psoriasis. Physician Global Assessment (PGA)
and Dermatology Life Quality Index (DLQI) will be used to assess effectiveness, safety
(tolerability), and duration of treatment response. This is a three year pragmatic,
randomized, active comparator effectiveness study.

NCTID
NCT03082729

A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis

Type:

Read More

Description

The primary objectives of this study are to determine the effect of apremilast on aortic
vascular inflammation, cardiometabolic biomarkers and body composition in patients with
moderate-severe psoriasis. FDG-PET/CT will be used to assess vascular inflammation, with
multi-volumetric product, tissue-to-background ratio and total atherosclerotic burden, and
body composition via volumetric quantification. This is a year-long, single arm, open label
study.